1. Introduction

Decentralized Genome Marketplaces are digital platforms that allow individuals, researchers, biotechnology companies, hospitals, pharmaceutical businesses and genetic-data intermediaries to exchange, license, share or commercialize genomic information through decentralized technologies.

These marketplaces may use:

Blockchain-based genomic data transactions.

Smart contracts for licensing genetic information.

Decentralized Autonomous Organizations (DAOs) for governance.

Token-based compensation for individuals sharing genomic data.

Federated databases for cross-border genomic research.

Artificial intelligence for genomic analysis and drug discovery.

Decentralized identity systems for genetic-data authentication.

For example, an individual may voluntarily provide genomic information to a decentralized platform. A pharmaceutical company may subsequently seek permission to use that information to identify disease-associated genetic variations or develop personalized medicines.

The central legal question is whether human genetic information can lawfully be exchanged as a commercial asset.

The important distinction is that the technology used to decentralize a marketplace does not exempt it from privacy, consent, intellectual-property, consumer-protection, contract, medical-research or data-protection laws.

There is no universally recognized legal framework that grants unrestricted ownership or commercial trading rights over human genomes.

2. Legal Nature of Decentralized Genome Marketplaces

The legality of these marketplaces depends on the legal classification of the information and materials being exchanged.

A. Genetic information as personal data

A person's DNA sequence can reveal highly sensitive information, including:

Hereditary disease risks.

Family relationships and biological parentage.

Ancestry and genetic characteristics.

Predisposition to certain medical conditions.

Information about biological relatives.

Under Article 9 of the European Union's General Data Protection Regulation (GDPR), genetic data is a special category of personal data. Its processing is generally prohibited unless a specified legal exception applies, such as explicit consent or another applicable statutory ground.

Consequently, a decentralized marketplace cannot lawfully treat identifiable genomic information as ordinary commercial data.

B. Biological samples versus digital genomic data

The law may distinguish between three separate assets:

Biological material: Blood, saliva, tissue and other physical samples.

Genomic information: DNA sequences and genetic analysis results.

Derived intellectual property: Patents, diagnostic methods, software and inventions developed using genomic information.

Ownership or control of one category does not automatically establish ownership of the other two.

For example, a research institution might lawfully possess a donated biological sample without obtaining unrestricted rights to disclose the donor's identifiable genomic information.

C. Commercial rights versus personal rights

A marketplace may grant a pharmaceutical company a licence to use genomic data for research. However, such a licence does not necessarily transfer the individual's privacy rights, dignity interests or statutory rights.

Therefore, the legal structure should distinguish:

Consent to collect genomic data.

Permission to process genomic data.

Permission to disclose data to third parties.

Permission to conduct commercial research.

Permission to develop commercial products.

Permission for subsequent or secondary uses.

These permissions should not be treated as interchangeable.

3. Major Legal Issues

A. Legality of selling human genomic data

The commercial exchange of genomic data is not necessarily unlawful. However, the transaction must comply with applicable privacy and research laws.

A marketplace should establish:

The identity and authority of the data contributor.

The legal basis for collecting the information.

The purpose for which the data will be used.

Whether commercial exploitation was disclosed.

Whether onward transfer is permitted.

Whether the data can be withdrawn or deleted where legally required.

A person may receive compensation for participating in a genomic research programme. Nevertheless, payment does not automatically make every subsequent use lawful.

B. Informed consent and commercial exploitation

Informed consent is one of the most important legal requirements.

A general agreement stating that a participant permits genetic research may not adequately authorize unrelated commercial activities.

For example, consent to participate in cancer research should not automatically authorize:

Selling genomic information to insurance companies.

Providing DNA profiles to employers.

Developing commercial ancestry databases.

Sharing genetic information with foreign pharmaceutical companies.

Using genetic information for unrelated AI training.

The marketplace must provide meaningful information about the purposes, recipients, risks and commercial consequences of data sharing.

C. Blockchain immutability and the right to deletion

Blockchain creates a particular legal problem because transactions recorded on distributed ledgers may be difficult or impossible to erase.

This creates tension with data-protection requirements concerning correction, erasure and withdrawal of consent.

Possible safeguards include:

Storing genomic information off-chain.

Recording only cryptographic hashes on-chain.

Using encrypted pointers to external databases.

Applying access revocation mechanisms.

Separating identity information from genomic records.

Establishing procedures for deleting or restricting off-chain information.

Encryption alone does not necessarily make personal data anonymous.

D. Smart-contract enforceability

Smart contracts can automatically execute transactions involving genomic information.

For example, a smart contract may release a research dataset after a pharmaceutical company makes payment.

However, automated execution cannot replace legal consent.

A smart contract may be technically operational but legally unenforceable if it involves unlawful data processing, deception, lack of capacity or an invalid contractual purpose.

Furthermore, contractual clauses should address errors, unauthorized disclosure, security incidents, compensation and dispute resolution.

E. Genetic discrimination

Decentralized marketplaces may increase the possibility of genetic discrimination if information becomes accessible to insurers, employers, financial institutions or other third parties.

Legal safeguards must prevent unauthorized use of genetic information to discriminate against individuals.

This issue is particularly important because genetic information can also reveal information about biological relatives who never participated in the marketplace.

4. Important Case Laws and Judicial Principles

The following cases provide important legal foundations. They do not directly establish a universal legal regime for blockchain-based genome marketplaces, but their principles are highly relevant.

1. Moore v. Regents of the University of California (1990)

Citation: 51 Cal. 3d 120, 793 P.2d 479 (1990).

Facts:

John Moore received medical treatment for hairy-cell leukaemia. Doctors obtained biological samples from him and developed a commercially valuable cell line without adequately disclosing their financial interests.

Moore argued that he had ownership rights in the biological materials and sought compensation for their commercial exploitation.

Judgment:

The California Supreme Court rejected his conversion claim based on ownership of the excised cells. However, it recognized that the doctors could face liability for breach of fiduciary duty and failure to obtain informed consent.

Legal principles:

Medical professionals must disclose relevant financial interests.

Informed consent is essential in medical research.

Commercial exploitation cannot justify concealing material information from patients.

Ownership of biological material and rights arising from medical relationships are distinct legal questions.

Application to genome marketplaces:

A marketplace should not conceal commercial arrangements between genomic-data contributors, platform operators and biotechnology companies.

A participant's consent must be informed about the commercial purposes of data processing.

Source:

Justia Law+1

2. Greenberg v. Miami Children's Hospital Research Institute (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Facts:

Families and organizations contributed biological materials and information to support research into Canavan disease.

Researchers subsequently developed a genetic diagnostic test and sought to commercialize the research results.

The contributors challenged the commercial exploitation and alleged that their contributions had been used beyond their expectations.

Judgment:

The court rejected several claims, including conversion, while considering the nature of the contributors' donations and the research arrangements.

Legal principles:

Donated biological materials do not necessarily remain the donor's property.

Research contributions and commercial expectations must be examined in their factual and contractual context.

Commercial development of research results raises questions different from ownership of donated samples.

Application:

Decentralized genome platforms should clearly explain whether participants are donating data, licensing it, or authorizing commercial research.

A platform should not assume that a research contribution creates an automatic entitlement to future royalties.

3. Washington University v. Catalona (2007)

Citation: 490 F.3d 667 (8th Cir. 2007).

Facts:

Patients had provided biological materials for genetic cancer research conducted through Washington University.

A dispute arose concerning whether the patients or the university controlled the samples when the researcher moved to another institution.

Judgment:

The Eighth Circuit upheld the university's ownership of the biological samples under the circumstances, finding that the donors had made valid gifts.

Legal principles:

Ownership of donated biological samples may vest in a research institution.

The terms and circumstances of donation matter.

Donors do not necessarily retain an unrestricted right to transfer samples.

Application:

A decentralized marketplace must distinguish between the custody of biological samples, ownership of physical materials and legal authority to process associated genetic data.

Justia Law+1

4. Association for Molecular Pathology v. Myriad Genetics (2013)

Citation: 569 U.S. 576 (2013).

Facts:

Myriad Genetics held patents concerning the BRCA1 and BRCA2 genes, which are associated with increased risks of breast and ovarian cancer.

The litigation concerned whether isolated naturally occurring DNA sequences could be patented.

Judgment:

The US Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated. However, synthetically created complementary DNA (cDNA) may be patent-eligible, subject to the applicable requirements.

Legal principles:

Naturally occurring genetic information is not automatically patentable.

Human ingenuity may create patentable subject matter.

Discovering or isolating a naturally occurring gene is different from creating an invention.

Application:

A decentralized genome marketplace cannot claim patent ownership over an individual's naturally occurring genome merely because it stores, sequences or tokenizes that genome.

A genuinely inventive diagnostic technology or engineered genetic application may raise a different intellectual-property question.

5. Justice K.S. Puttaswamy v. Union of India (2017)

Citation: (2017) 10 SCC 1.

Facts:

The constitutional validity of the Aadhaar framework raised significant questions concerning privacy, personal information and state surveillance.

Judgment:

A nine-judge bench of the Supreme Court of India unanimously recognized privacy as a fundamental right protected under Article 21 and other freedoms guaranteed by Part III of the Constitution.

Legal principles:

Informational privacy is constitutionally protected.

Personal autonomy and dignity are central to privacy.

Collection and use of personal information require a constitutionally valid legal basis.

Restrictions on privacy must satisfy applicable constitutional requirements.

Application:

Genomic information is especially sensitive because it can reveal intimate biological characteristics and family relationships.

In India, this constitutional framework is important when examining governmental access to genomic databases and the legal safeguards surrounding state-sponsored genetic information systems.

6. Samira Kohli v. Dr. Prabha Manchanda (2008)

Citation: (2008) 2 SCC 1.

Facts:

The case concerned medical treatment performed beyond the scope of the patient's consent.

Judgment:

The Supreme Court emphasized that valid medical consent must be voluntary and based on adequate information. Consent to one procedure does not automatically authorize a materially different procedure.

Legal principles:

Consent must be informed.

Consent must be voluntary.

The scope of consent matters.

Medical necessity does not provide unrestricted authority to disregard consent.

Application:

A genomic marketplace should not interpret consent to DNA testing as unrestricted consent to commercial distribution, AI analysis, genetic profiling or unrelated research.

5. Indian Legal Framework

India presents an important jurisdiction for decentralized genome marketplaces because genomic information may involve medical research, biotechnology commercialization, personal-data processing and biological-resource access.

A. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 establishes a framework governing the processing of digital personal data.

Important provisions include:

Section 4: Lawful processing of personal data.

Section 5: Notice requirements.

Section 6: Consent requirements and withdrawal.

Section 8: General obligations of data fiduciaries.

Section 11: Right to access information about personal data.

Section 12: Right to correction and erasure.

Section 13: Right of grievance redressal.

Section 17: Certain exemptions.

A decentralized genomic platform that determines the purpose and means of processing personal data may qualify as a Data Fiduciary.

An organization processing genomic information on behalf of another organization may have obligations as a Data Processor.

Important commencement qualification: India notified the DPDP Act's staggered commencement through G.S.R. 843(E), dated 13 November 2025. The principal processing provisions, including Sections 3–17, are scheduled to commence 18 months after publication, on 13 May 2027. Therefore, as of 5 November 2026, those substantive provisions have not yet commenced. The platform must account for the applicable existing legal framework during this transitional period.

India Code+1

B. Information Technology Act, 2000

The Information Technology Act, 2000, and the applicable rules concerning sensitive personal information are relevant to digital genomic platforms.

Section 43A and the Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011, have historically provided important safeguards for sensitive personal information.

Their applicability and continuing operation must be assessed alongside the staggered commencement of the DPDP Act and its repeal-related provisions.

A marketplace should maintain reasonable security practices, confidentiality arrangements and safeguards against unauthorized disclosure.

C. ICMR National Ethical Guidelines

The Indian Council of Medical Research (ICMR) National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, provide important ethical guidance for genetic and genomic research.

Relevant principles include:

Informed consent from research participants.

Confidentiality of genetic information.

Protection of vulnerable participants.

Appropriate ethical committee review.

Restrictions on secondary use beyond the original consent.

Genetic counselling where appropriate.

The guidelines also recognize that genetic research may involve information about family members who have not directly participated in the research.

Therefore, a decentralized genome marketplace should consider the privacy interests of genetic relatives as well as the person who supplied the DNA sample.

Indian Council of Medical Research+1

D. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 is relevant where marketplace activities involve biological resources falling within its scope.

The Biological Diversity (Amendment) Act, 2023 introduced changes concerning access, research, commercial utilization and benefit-sharing requirements.

Depending on the parties, biological material, activities and applicable statutory provisions, prior approval, intimation or other compliance requirements may apply.

The National Biodiversity Authority and State Biodiversity Boards have relevant regulatory roles.

A genomic marketplace cannot assume that digitizing biological information removes all obligations associated with access to the underlying biological resources.

National Biodiversity Authority

E. Indian Constitutional Privacy Protection

Article 21 of the Constitution protects personal liberty and privacy.

The principles in Justice K.S. Puttaswamy v. Union of India are particularly relevant when genomic databases are accessed by public authorities or used in systems involving state surveillance.

A government-operated genomic marketplace would therefore need to satisfy applicable constitutional requirements concerning legality, legitimate objectives and proportionality.

6. International Legal Framework

A. European Union: GDPR

The GDPR provides particularly significant protection for genomic marketplaces.

Important provisions include:

Article 9 is particularly important because genetic data receives special-category protection.

For instance, a European genomic marketplace generally cannot disclose identifiable genetic information to a pharmaceutical company merely because that company pays a transaction fee. It must establish the applicable legal basis and satisfy the relevant safeguards.

European Commission+1

B. United States: Genetic Information Nondiscrimination Act

The Genetic Information Nondiscrimination Act 2008 (GINA) provides protection against certain forms of genetic discrimination.

Its principal protections concern:

Health insurance.

Employment.

However, GINA does not provide comprehensive protection against every possible use of genetic information. For example, life insurance, disability insurance and long-term-care insurance are not generally covered by its principal insurance protections.

Accordingly, genome marketplaces should not advertise genetic-data sharing as completely protected from all forms of discrimination.

C. UNESCO Declaration on the Human Genome and Human Rights

The 1997 UNESCO Universal Declaration on the Human Genome and Human Rights recognizes the human genome as the heritage of humanity in a symbolic sense.

It emphasizes human dignity, fundamental rights, informed consent, confidentiality and the prohibition of genetic discrimination.

It is an important international ethical instrument, although it is not equivalent to a directly enforceable domestic commercial licensing statute.

7. Decentralized Autonomous Organizations and Legal Liability

Some genomic marketplaces are governed by Decentralized Autonomous Organizations (DAOs).

A DAO may allow token holders to vote on:

Which genomic datasets should be licensed.

Which research organizations receive access.

How platform revenue is distributed.

Which scientific projects receive funding.

Whether commercial transactions should be approved.

However, decentralization creates important legal difficulties.

First: Identification of responsible parties.

If an unauthorized genomic disclosure occurs, the affected individual may face difficulty identifying the legally responsible organization or person.

Second: Regulatory accountability.

A DAO cannot automatically avoid applicable privacy and consumer-protection laws merely because its decisions are made through blockchain voting.

Third: Contractual liability.

Smart-contract developers, platform operators, data custodians and participating businesses may have different legal responsibilities depending on their actual roles and conduct.

Fourth: Token-related regulation.

If the marketplace issues transferable tokens representing investment rights, revenue participation or financial returns, applicable securities and financial regulations may become relevant.

Fifth: Jurisdictional conflicts.

A DAO may have contributors in India, developers in Europe, servers in the United States and pharmaceutical customers in several countries. This creates complex questions of jurisdiction, applicable law and cross-border enforcement.

8. Intellectual Property and Genome Marketplace Transactions

A genome marketplace may generate intellectual-property disputes involving three different categories.

A. Naturally occurring genetic sequences

Natural genetic sequences are not automatically patentable merely because they have been isolated or digitized.

The principle in Association for Molecular Pathology v. Myriad Genetics is important here.

B. Artificially developed genomic technologies

Patent protection may be available for qualifying inventions involving:

Engineered genetic constructs.

Novel diagnostic technologies.

New laboratory processes.

Inventive bioinformatics technologies.

Certain synthetic biological applications.

Patentability depends on the applicable jurisdiction and statutory requirements.

C. Copyright and database rights

A raw genetic sequence, as a naturally occurring biological fact, should not automatically be treated as copyrightable subject matter.

However, original software, qualifying database structures, technical documentation and creative analytical materials may receive intellectual-property protection.

A marketplace should also distinguish intellectual-property ownership from permission to access or process the underlying personal data.

9. Consumer Protection and Unfair Commercial Practices

Genomic marketplaces may make commercial claims such as:

Earn money by selling your DNA.

Receive royalties from every research transaction.

Maintain complete control over your genome.

Your genetic information is permanently anonymous.

Blockchain guarantees total genetic privacy.

Such statements may be misleading if they exaggerate the legal rights or technological safeguards actually available.

Consumer-protection law may apply where a platform misrepresents its privacy protections, payment arrangements, medical benefits or commercial services.

Platforms should clearly disclose:

The amount of compensation.

Whether payments are one-time or recurring.

The duration of data licences.

Whether data may be sublicensed.

The possibility of re-identification.

Whether withdrawal terminates future use or affects existing research.

The identity of commercial recipients.

10. Major Legal Risks and Compliance Requirements

11. Hypothetical Judicial Dispute

Consider the following situation.

A decentralized genomic marketplace called GenomeChain collects DNA information from 50,000 individuals. Participants receive digital tokens in exchange for sharing their genomic profiles.

A pharmaceutical company subsequently purchases access to the dataset to develop a personalized cancer treatment.

The company discovers commercially valuable genetic patterns and develops a patented diagnostic technology.

However, several participants allege that:

They never consented to commercial pharmaceutical research.

The marketplace failed to disclose the intended commercial use.

Their genomic information was shared with foreign researchers.

They were promised continuing royalties but received only initial token payments.

Their genetic information cannot be deleted from the blockchain.

Possible legal proceedings:

Privacy and data-protection claims against responsible platform entities.

Breach-of-contract claims concerning the licensing agreement.

Consumer-protection proceedings concerning misleading commercial representations.

Claims concerning unauthorized research or disclosure.

Intellectual-property disputes concerning the resulting diagnostic technology.

The court would need to distinguish between the validity of the original consent, the rights in the biological samples, the legal basis for processing genomic data, the enforceability of token agreements and ownership of the resulting invention.

The principles in Moore, Greenberg, Catalona, Myriad Genetics and Puttaswamy would provide relevant legal guidance, depending on the jurisdiction.

12. Recommendations for a Legally Compliant Genome Marketplace

A legally responsible decentralized genome marketplace should incorporate the following framework.

1. Consent-based participation: Obtain clear, specific and informed authorization.

2. Purpose limitation: Restrict genomic data processing to disclosed and legally authorized purposes.

3. Commercial transparency: Explain payments, royalties, sublicensing and commercial exploitation.

4. Privacy-preserving blockchain: Keep identifiable genomic records off-chain wherever practicable.

5. Independent governance: Establish an identifiable legal entity responsible for compliance.

6. Ethical review: Obtain appropriate research ethics committee review where human-participant research requirements apply.

7. Genetic discrimination protection: Restrict access and prohibit unauthorized discriminatory uses.

8. Cross-border compliance: Assess applicable data-protection laws in every relevant jurisdiction.

9. Intellectual-property clarity: Distinguish participant rights, sample ownership, data licences and inventions.

10. Effective remedies: Provide grievance procedures, compensation mechanisms and legally compliant withdrawal and deletion procedures.

13. Conclusion

The legality of decentralized genome marketplaces depends on the interaction of privacy law, biotechnology regulation, intellectual-property law, contractual obligations, consumer protection and constitutional rights.

The central legal principle is that human genomic information cannot be treated as an unrestricted commercial commodity simply because it is placed on a decentralized blockchain network.

An individual may authorize particular commercial uses of genomic information, subject to applicable law. However, such authorization does not necessarily transfer ownership of the person's genome or eliminate the individual's privacy and dignity interests.

The judicial reasoning in Moore, Greenberg, Catalona, Myriad Genetics and Puttaswamy demonstrates the importance of separating biological ownership, informed consent, commercial exploitation, intellectual property and personal privacy.

Future regulation will need to address a particularly difficult question: how can individuals participate in the economic benefits of genomic research without losing meaningful control over their genetic identity?

14. Important Legal References

Selected primary and institutional sources:

India – Digital Personal Data Protection Act, 2023

India – DPDP commencement notification, 2025

ICMR – National Ethical Guidelines

European Commission – GDPR sensitive data

Moore v. Regents – Full judgment

Washington University v. Catalona – Judgment

Legal research note: This is a comparative academic analysis, not a determination that every cited legal rule applies in every country. The cases are judicial precedents from their respective jurisdictions, and the Indian DPDP commencement schedule is particularly important when assessing present-day compliance.

I can also develop this subject into a research-paper chapter covering Decentralized Genome Marketplaces Governance, Accountability and Regulatory Doctrine, with additional case laws and comparative analysis of India, Australia, the USA and the EU.